Literature DB >> 18953713

Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine.

Robert Thimme1, Christoph Neumann-Haefelin, Tobias Boettler, Hubert E Blum.   

Abstract

Hepatitis C virus (HCV) causes chronic infection in approximately two-thirds of cases, leading to chronic hepatitis, liver cirrhosis, liver disease, liver failure, and hepatocellular carcinoma in a substantial proportion of the 170 million HCV-infected individuals worldwide. It is generally accepted that the cellular immune response plays the most important role in determining the outcome of HCV infection. First, vigorous, multispecific and sustained CD4+ and CD8+ T-cell responses are associated with viral clearance. Second, depletion studies in chimpanzees, the only other host of HCV besides humans, have shown that both CD4+ and CD8+ T-cells are required for virus elimination. Third, the host's human leukocyte antigen alleles, which restrict the repertoire of CD4+ and CD8+ T-cell responses, influence the outcome of infection. Of note, protective immunity has been demonstrated in population-based studies, as well as in experimentally infected chimpanzees. Thus, a detailed understanding of the mechanisms contributing to the failure of the antiviral immune response should allow successful development of prophylactic and therapeutic vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18953713     DOI: 10.1515/bc.2008.061

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  17 in total

1.  HCV entry and neutralizing antibodies: lessons from viral variants.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

Review 2.  Common threads in persistent viral infections.

Authors:  Melissa Kane; Tatyana Golovkina
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

3.  Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.

Authors:  Mark H Kuniholm; Xianhong Xie; Kathryn Anastos; Robert C Kaplan; Xiaonan Xue; Andrea Kovacs; Marion G Peters; Eric C Seaberg; Audrey L French; Mary A Young; Michael Augenbraun; Jeffrey A Martinson; Kristin A Bush; Alan L Landay; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

4.  Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.

Authors:  Dorothea Bankwitz; Eike Steinmann; Julia Bitzegeio; Sandra Ciesek; Martina Friesland; Eva Herrmann; Mirjam B Zeisel; Thomas F Baumert; Zhen-yong Keck; Steven K H Foung; Eve-Isabelle Pécheur; Thomas Pietschmann
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

5.  Development of a multiplex bead-based assay for detection of hepatitis C virus.

Authors:  Bruna P F Fonseca; Christiane F S Marques; Lílian D Nascimento; Marcelle B Mello; Leila B R Silva; Nara M Rubim; Leonardo Foti; Edimilson D Silva; Antonio G P Ferreira; Marco A Krieger
Journal:  Clin Vaccine Immunol       Date:  2011-02-23

6.  Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences.

Authors:  Claro Yu; Denali Boon; Shannon L McDonald; Timothy G Myers; Keiko Tomioka; Hanh Nguyen; Ronald E Engle; Sugantha Govindarajan; Suzanne U Emerson; Robert H Purcell
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

7.  Dynamic coinfection with multiple viral subtypes in acute hepatitis C.

Authors:  Jennifer A Smith; Judith H Aberle; Vicki M Fleming; Peter Ferenci; Emma C Thomson; Peter Karayiannis; Angela R McLean; Heidemarie Holzmann; Paul Klenerman
Journal:  J Infect Dis       Date:  2010-11-10       Impact factor: 5.226

Review 8.  HCV drug discovery aimed at viral eradication.

Authors:  R F Schinazi; L Bassit; C Gavegnano
Journal:  J Viral Hepat       Date:  2009-12-18       Impact factor: 3.728

9.  B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.

Authors:  Barton F Haynes; Garnett Kelsoe; Stephen C Harrison; Thomas B Kepler
Journal:  Nat Biotechnol       Date:  2012-05-07       Impact factor: 54.908

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.